Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 5.42 6.48% 0.33
PIRS closed up 6.48 percent on Friday, September 13, 2019, on 85 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PIRS trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength 6.48%
Upper Bollinger Band Walk Strength 6.48%
Overbought Stochastic Strength 6.48%
Upper Bollinger Band Touch Strength 6.48%
Upper Bollinger Band Touch Strength 5.65%
20 DMA Support Bullish 1.88%
Crossed Above 50 DMA Bullish 1.88%

Older signals for PIRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Medicine Chemistry Cancers Dialysis Membrane Technology Asthma Chronic Kidney Disease Anatomy Inflammatory Diseases End Stage Renal Disease Kidney Diseases Hepatology Kidney Hepcidin Treatment Of Various Types Of Cancers
Is PIRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.04
52 Week Low 2.39
Average Volume 559,456
200-Day Moving Average 3.71
50-Day Moving Average 4.8316
20-Day Moving Average 4.806
10-Day Moving Average 4.946
Average True Range 0.3742
ADX 15.1
+DI 22.415
-DI 13.4857
Chandelier Exit (Long, 3 ATRs ) 4.3674
Chandelier Exit (Short, 3 ATRs ) 5.4426
Upper Bollinger Band 5.3589
Lower Bollinger Band 4.2531
Percent B (%b) 1.06
BandWidth 23.008739
MACD Line 0.0888
MACD Signal Line 0.0177
MACD Histogram 0.0711
Fundamentals Value
Market Cap 240.15 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -7.63
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.05
Resistance 3 (R3) 6.00 5.75 5.94
Resistance 2 (R2) 5.75 5.59 5.77 5.91
Resistance 1 (R1) 5.58 5.49 5.66 5.63 5.87
Pivot Point 5.33 5.33 5.37 5.35 5.33
Support 1 (S1) 5.16 5.17 5.25 5.21 4.97
Support 2 (S2) 4.91 5.07 4.93 4.93
Support 3 (S3) 4.75 4.91 4.90
Support 4 (S4) 4.79